Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate
Summary: The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
iScience - 26(2023), 11, Seite 108147- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ryuta Uraki [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1016/j.isci.2023.108147 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091942950 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091942950 | ||
| 003 | DE-627 | ||
| 005 | 20240412110618.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.isci.2023.108147 |2 doi | |
| 035 | |a (DE-627)DOAJ091942950 | ||
| 035 | |a (DE-599)DOAJbcc9e8dce069400aa6ad9a843503c254 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a Ryuta Uraki |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Summary: The emergence and spread of new SARS-CoV-2 variants with mutations in the spike protein, such as the XBB.1.5 and XBB.1.9.1 sublineages, raise concerns about the efficacy of current COVID-19 vaccines and therapeutic monoclonal antibodies (mAbs). In this study, none of the mAbs we tested neutralized XBB.1.9.1 or XBB.1.5, even at the highest concentration used. We also found that the bivalent mRNA vaccine could enhance humoral immunity against XBB.1.9.1, but that XBB.1.9.1 and XBB.1.5 still evaded humoral immunity induced by vaccination or infection. Moreover, the susceptibility of XBB.1.9.1 to remdesivir, molnupiravir, nirmatrelvir, and ensitrelvir was similar to that of the ancestral strain and the XBB.1.5 isolate in vitro. Finally, we found the replicative fitness of XBB.1.9.1 to be similar to that of XBB.1.5 in hamsters. Our results suggest that XBB.1.9.1 and XBB.1.5 have similar antigenicity and replicative ability, and that the currently available COVID-19 antivirals remain effective against XBB.1.9.1. | ||
| 650 | 4 | |a Virology | |
| 650 | 4 | |a Clinical microbiology | |
| 653 | 0 | |a Science | |
| 653 | 0 | |a Q | |
| 700 | 0 | |a Mutsumi Ito |e verfasserin |4 aut | |
| 700 | 0 | |a Maki Kiso |e verfasserin |4 aut | |
| 700 | 0 | |a Seiya Yamayoshi |e verfasserin |4 aut | |
| 700 | 0 | |a Kiyoko Iwatsuki-Horimoto |e verfasserin |4 aut | |
| 700 | 0 | |a Yuko Sakai-Tagawa |e verfasserin |4 aut | |
| 700 | 0 | |a Masaki Imai |e verfasserin |4 aut | |
| 700 | 0 | |a Michiko Koga |e verfasserin |4 aut | |
| 700 | 0 | |a Shinya Yamamoto |e verfasserin |4 aut | |
| 700 | 0 | |a Eisuke Adachi |e verfasserin |4 aut | |
| 700 | 0 | |a Makoto Saito |e verfasserin |4 aut | |
| 700 | 0 | |a Takeya Tsutsumi |e verfasserin |4 aut | |
| 700 | 0 | |a Amato Otani |e verfasserin |4 aut | |
| 700 | 0 | |a Shuetsu Fukushi |e verfasserin |4 aut | |
| 700 | 0 | |a Shinji Watanabe |e verfasserin |4 aut | |
| 700 | 0 | |a Tadaki Suzuki |e verfasserin |4 aut | |
| 700 | 0 | |a Tetsuhiro Kikuchi |e verfasserin |4 aut | |
| 700 | 0 | |a Hiroshi Yotsuyanagi |e verfasserin |4 aut | |
| 700 | 0 | |a Ken Maeda |e verfasserin |4 aut | |
| 700 | 0 | |a Yoshihiro Kawaoka |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t iScience |d Elsevier, 2019 |g 26(2023), 11, Seite 108147- |w (DE-627)DOAJ000121363 |x 25890042 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2023 |g number:11 |g pages:108147- |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.isci.2023.108147 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/bcc9e8dce069400aa6ad9a843503c254 |z kostenfrei |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S2589004223022241 |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2589-0042 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2023 |e 11 |h 108147- | ||